Nektar Forms New Subsidiary in Anticipation of Opioid Medication Approval
Inheris Biopharma was formed as Nektar awaits the FDA approval of a pain medication that does not have the euphoric side effects of other opioids.
The Home of the Life Sciences Industry
Explore Latest News
Novartis' SMA Gene Therapy Treatment Approved by FDA, Priced at $2.125 Million
The price of the one-and-done gene therapy treatment is about half of what was initially projected by Novartis.
- Dynavax to Lay Off 37% of Staff, CEO to Retire as Company Restructures
- Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
- Research Roundup: Dog Ownership, Diabetes, Alzheimer’s, HIV Vaccine and More
- Tonix Pharma In-Licenses Drug to Treat Cocaine Intoxication
- BioSpace Movers and Shakers, May 24
Get personalized job alerts
Create a job alert and receive custom job recommendations straight to your inbox.
Employers
Post jobs on BioSpace and start building your talent pipeline today. Click the button to access our easy eCommerce site, which lets you purchase and post jobs in just a few clicks.